난소암 진단 시장 : 제품 유형별, 진단 검사별, 암 유형별, 최종 용도별, 세계 예측(2024-2032년)

Global Ovarian Cancer Diagnostic Market size will witness a 6.6% CAGR between 2024 and 2032, driven by increasing research and development efforts in the field. With ovarian cancer being notoriously difficult to detect in its early stages, there is a pressing need for improved diagnostic tools and techniques. For instance, in January 2024, researchers at the Georgia Tech Integrated Cancer Research Center (ICRC) integrated machine learning techniques with data on blood metabolites to create a novel test capable of identifying ovarian cancer with 93% accuracy in samples from their study cohort.

As researchers delve deeper into understanding the molecular mechanisms and biomarkers associated with ovarian cancer, innovative diagnostic methods are emerging. These advancements include liquid biopsy techniques, genomic profiling, and imaging modalities, offering more accurate and timely disease detection. As a result, healthcare providers and patients alike are increasingly turning to these cutting-edge diagnostic solutions, driving market demand and fostering hope for improved outcomes in ovarian cancer diagnosis and treatment.

The overall Ovarian Cancer Diagnostic Industry is classified based on the product type, cancer type, diagnostic tests, end-use, and region.

The consumables segment will register a significant CAGR from 2024 to 2032. These essential components, such as test kits, reagents, and disposable instruments, are crucial for conducting diagnostic procedures accurately and efficiently. As healthcare providers prioritize early detection and personalized treatment approaches, the demand for high-quality consumables in ovarian cancer diagnostics continues to grow. Moreover, technological upgrades and the introduction of innovative consumable products further fuel market demand, ensuring that healthcare professionals have access to reliable tools for effective diagnosis and management of ovarian cancer.

The ovarian cancer diagnostic market share from blood test segment will record noteworthy gains from 2024 to 2032. These tests analyze specific biomarkers or genetic signatures in the blood associated with ovarian cancer, offering a convenient and efficient diagnostic solution. As healthcare providers emphasize early detection and personalized treatment strategies, the demand for blood-based diagnostic tests continues to rise. Moreover, ongoing research and advancements in blood test technologies further drive market growth, ensuring improved outcomes for patients through timely detection and intervention.

Asia Pacific cancer ovarian cancer diagnostic market will register a commendable market share through 2032. With a rising prevalence of ovarian cancer and increasing awareness about early detection, there is a growing demand for reliable diagnostic tools in countries across the Asia Pacific. Healthcare systems are prioritizing screening programs and access to advanced diagnostic technologies to improve patient outcomes. As a result, the demand for ovarian cancer diagnostic tests, including imaging techniques and biomarker assays, continues to escalate, driving market growth and fostering advancements in healthcare delivery throughout the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence and prevalence of ovarian cancer
    • 3.2.1.2 Growing awareness and screening programs
    • 3.2.1.3 Increasing research and development activities
    • 3.2.1.4 Technological advancements in ovarian cancer diagnostics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments/analyzers
• 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Diagnostic Tests, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Imaging test
  • 6.2.1 Ultrasound
  • 6.2.2 CT scan
  • 6.2.3 MRI scan
  • 6.2.4 PET scan
  • 6.2.5 Other imaging tests
• 6.3 Blood test
  • 6.3.1 CA125 (Cancer antigen 125)
  • 6.3.2 HER2 (Human epidermal growth factor receptor 2)
  • 6.3.3 BRCA (Breast cancer gene)
  • 6.3.4 CEA (Carcinoembryonic antigen)
  • 6.3.5 ER & PR (Estrogen receptor and progesterone receptor)
  • 6.3.6 KRAS mutation
  • 6.3.7 Other blood tests
• 6.4 Biopsy
• 6.5 Other diagnostic tests

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Epithelial tumor
• 7.3 Germ cell tumor
• 7.4 Stromal cell tumor
• 7.5 Other cancer types

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic laboratories
• 8.4 Diagnostic imaging centers
• 8.5 Cancer research institutes
• 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Agilent Technologies
• 10.3 Canon Medical Systems Corporation
• 10.4 Danaher Corporation
• 10.5 F. Hoffmann-La Roche Ltd.
• 10.6 Fujirebio Diagnostics
• 10.7 GE HealthCare Technologies Inc.
• 10.8 Illumina Inc.
• 10.9 Myriad Genetics
• 10.10 Philips Healthcare
• 10.11 Positron Corporation
• 10.12 Qiagen N.V.
• 10.13 Quest Diagnostics
• 10.14 Siemens Healthineers AG